作者: Cristiana Pistol Tanase , Monica Neagu , Radu Albulescu , Mihail Eugen Hinescu
DOI: 10.1016/S0065-2423(10)51006-0
关键词:
摘要: Pancreatic cancer represents a major challenge for research studies and clinical management. No specific tumor marker the diagnosis of pancreatic exists. Therefore, extensive genomic, transcriptomic, proteomic are being developed to identify candidate markers use in high-throughput systems capable large cohort screening. Understandably, complex pathophysiology requires sensitive biomarkers that can improve both early therapeutic monitoring. The lack single diagnostic makes it likely only panel is providing appropriate combination high sensitivity specificity. Biomarker discovery using novel technology prognostic upgrading pinpoint new molecular targets innovative therapy.